85849-94-1

Basic information

• Product Name: 3-METHYL-2-[(PHENYLSULFONYL)AMINO]BUTANOIC ACID
• Synonyms: (S)-3-methyl-2-(phenylsulfonamido)butanoic acid;(2S)-2-benzenesulfonamido-3-methylbutanoic acid
• CAS NO: 85849-94-1
• Molecular Formula: C₁₁H₁₅NO₄S
• Molecular Weight: 257.31
• Mol File: 85849-94-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 431.5°C at 760 mmHg
• Flash Point: 214.7°C
• Appearance: /
• Vapor Pressure: 3.28E-08mmHg at 25°C
• CAS DataBase Reference: 3-METHYL-2-[(PHENYLSULFONYL)AMINO]BUTANOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 3-METHYL-2-[(PHENYLSULFONYL)AMINO]BUTANOIC ACID(85849-94-1)
• EPA Substance Registry System: 3-METHYL-2-[(PHENYLSULFONYL)AMINO]BUTANOIC ACID(85849-94-1)

Safety Data

• Hazardous Substances Data: 85849-94-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H15NO4S/c1-8(2)10(11(13)14)12-17(15,16)9-6-4-3-5-7-9/h3-8,10,12H,1-2H3,(H,13,14)/p-1/t10-/m1/s1

Upstream product

• 72-18-4 L-valine 
• 191792-79-7 (S)-2-benzenesulfonylamino-3-methylbutyric acid ethyl ester 
• 98-09-9 benzenesulfonyl chloride 
• 17431-03-7 L-valine ethyl ester 

Downstream Products

• 270071-99-3 (S)-2-(Benzenesulfonyl-benzyl-amino)-3-methyl-butyric acid 
• 543725-75-3 N-{(S)-1-[1-(4-Chloro-phenyl)-meth-(E)-ylidene-hydrazinocarbonyl]-2-methyl-propyl}-benzenesulfonamide 
• 543725-68-4 N-[2-methyl-1-(3-methyl-5-oxo-4,5-dihydro-pyrazole-1-carbonyl)-propyl]-benzenesulfonamide 
• 543725-60-6 N-(1-hydrazinocarbonyl-2-methyl-propyl)-benzenesulfonamide 
• 197521-39-4 (S)-2-Benzenesulfonylamino-3-methyl-butyric acid methyl ester 

Relevant articles and documents

Synthesis and biological evaluation of Val–Val dipeptide–sulfonamide conjugates

Novel Val–Val dipeptide–benzenesulfonamide conjugates were reported in this study. These were achieved by a condensation reaction of p-substituted benzenesulfonamoyl alkanamides with 2-amino-4-methyl-N-substituted phenyl butanamide using classical peptide

Synthesis of novel heterocyclic sulfonamides as protease inhibitors of HIV-1

Background: HIV-1 protease is a prime target for drug therapy due to its integral role in HIV viral replication. Several protease inhibitors such as lopinavir and tipranavir were shown to possess potent inhibitory activities against the HIV virus. Due to the high mutation rate of HIV, resistance remains a major problem in the treatment of this virus and design and synthesis of new protease inhibitors is an area of continued interest in new drug discovery research. Methods: Utilizing the key fragments of structures of both peptide-based and non-peptide-based protease inhibitors lopinavir and tipranavir, we explored designing some new compounds. Results: Six new protease inhibitors were designed and synthesized based on the key structural fragments in lopinavir and tipranavir. The designed new compounds contain heterocyclic groups such as thiophene, isoxazole, and imidazole groups, and the best compound exhibited 0.6 nm of the protease inhibitory activity. Conclusion: We have prepared some novel heterocyclic sulfonamides utilizing a key fragment based approach by recombining structural fragments of the potent protease inhibitors lopinavir and tipranavir. Some of these newly designed compounds showed good to excellent HIV-1 protease inhibitory activity, which indicated that this method would be useful for the discovery of new drug lead compounds that target HIV.

Evaluation of Antibacterial and Antifungal Effects of Novel Hydroxamic Acids Linked-natural Amino Acids

A SERIES of new derivatives containing hydroxamic acids linked-amino acids has been synthesized and fully characterized by spectroscopic techniques including; 1H, 13C, DEPT 135 and HRMS.These new compounds were tested for their antib